Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 10:00 PM
Aeglea BioTherapeutics Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|
| Development Fee Revenue | 2.33M | 6.74M |
| Development Fee Revenue Growth | -65.44% | n/a |
| License Revenue | n/a | 12M |
| License Revenue Growth | -100.00% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.94M | 19.9M | 10.65M | 11.51M | 8.58M | 12.06M | 5.23M | 5.08M | 6.95M | 7.67M | 8.82M | 7.3M | 6.84M | 6.82M | 6.35M | 7.02M | 5.67M | 4.69M | 4.46M | 4.34M | 4.31M | 3.82M | 3.27M | 3.51M | 3.31M | 2.93M | 2.88M | 2.32M | 3.02M | 2.36M | 2.36M | 2.05M | 2.06M | 2.45M | 1.83M | 1.62M | 1.36M | 2.12M | 847K |
| Selling, General, and Administrative Revenue Growth | -39.99% | +86.91% | -7.50% | +34.10% | -28.83% | +130.72% | +2.93% | -26.94% | -9.42% | -13.03% | +20.82% | +6.80% | +0.25% | +7.37% | -9.49% | +23.77% | +20.91% | +5.18% | +2.69% | +0.84% | +12.87% | +16.77% | -6.81% | +5.82% | +13.26% | +1.42% | +24.51% | -23.28% | +27.75% | 0.00% | +15.37% | -0.77% | -15.65% | +33.77% | +13.24% | +18.74% | -35.89% | +150.65% | n/a |
| Research and Development Revenue | 41.62M | 106.97M | 44.74M | 32.64M | 24.66M | 17.39M | 13.78M | 14.25M | 11.98M | 15.37M | 16.98M | 16.78M | 14.85M | 13.58M | 11.86M | 15.76M | 12.45M | 16.87M | 14.56M | 17.57M | 17.84M | 14.81M | 14.39M | 11.8M | 8.93M | 9.12M | 6.87M | 5.79M | 6.24M | 5.83M | 4.95M | 4.74M | 5.38M | 4.42M | 3.6M | 3.97M | 3.13M | 2.74M | 1.62M |
| Research and Development Revenue Growth | -61.09% | +139.07% | +37.10% | +32.34% | +41.84% | +26.20% | -3.33% | +18.99% | -22.09% | -9.45% | +1.17% | +12.99% | +9.38% | +14.54% | -24.76% | +26.54% | -26.19% | +15.84% | -17.10% | -1.53% | +20.48% | +2.90% | +21.96% | +32.13% | -2.12% | +32.78% | +18.63% | -7.18% | +6.92% | +17.90% | +4.39% | -11.96% | +21.83% | +22.91% | -9.33% | +26.75% | +14.36% | +68.68% | n/a |